VNA
ARKG icon

Valley National Advisers’s ARK Genomic Revolution ETF ARKG Stock Holding History

Valley National Advisers’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Buy
5,611
+833
+17% +$26.5K 0.03% 238
2026
Q1 		$126K Sell
4,778
-170
-3% -$4.98K 0.02% 291
2025
Q4 		$143K Buy
4,948
+227
+5% +$6.81K 0.02% 279
2025
Q3 		$131K Sell
4,721
-650
-12% -$16.4K 0.02% 274
2025
Q2 		$130K Sell
5,371
-1,001
-16% -$21.9K 0.02% 280
2025
Q1 		$132K Buy
+6,372
New +$160K 0.02% 261
2024
Q2 		– Sell
-1,089
Closed -$31K – 1175
2024
Q1 		$31K Sell
1,089
-715
-40% -$21.5K ﹤0.01% 469
2023
Q4 		$59K Sell
1,804
-1,377
-43% -$37.4K 0.01% 379
2023
Q3 		$89K Sell
3,181
-1,123
-26% -$36.7K 0.02% 311
2023
Q2 		$147K Hold
4,304
– – 0.02% 270
2023
Q1 		$130K Sell
4,304
-15
-0.3% -$465 0.02% 272
2022
Q4 		$135K Sell
4,319
-4,045
-48% -$128K 0.02% 273
2022
Q3 		$271K Sell
8,364
-15,011
-64% -$551K 0.06% 213
2022
Q2 		$880K Buy
23,375
+3,113
+15% +$109K 0.19% 100
2022
Q1 		$931K Sell
20,262
-14,744
-42% -$703K 0.18% 119
2021
Q4 		$2.14M Sell
35,006
-64
-0.2% -$4.42K 0.4% 70
2021
Q3 		$2.62M Buy
35,070
+2,482
+8% +$208K 0.47% 44
2021
Q2 		$3.01M Buy
32,588
+3,202
+11% +$272K 0.55% 30
2021
Q1 		$2.61M Buy
29,386
+2,013
+7% +$200K 0.51% 35
2020
Q4 		$2.55M Buy
27,373
+5,333
+24% +$425K 0.54% 33
2020
Q3 		$1.4M Buy
22,040
+1,886
+9% +$111K 0.32% 52
2020
Q2 		$1.05M Sell
20,154
-1,027
-5% -$44K 0.24% 70
2020
Q1 		$663K Sell
21,181
-2,821
-12% -$94.3K 0.18% 92
2019
Q4 		$805K Buy
24,002
+10,088
+73% +$320K 0.2% 90
2019
Q3 		$411K Buy
13,914
+2,362
+20% +$76.8K 0.11% 130
2019
Q2 		$398K Buy
11,552
+1,574
+16% +$50.5K 0.11% 127
2019
Q1 		$328K Buy
9,978
+9,369
+1,538% +$277K 0.09% 142
2018
Q4 		$15K Buy
+609
New +$17.2K ﹤0.01% 400

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Valley National Advisers's ARKG Position: Q2 2026 in Review

Valley National Advisers increased its ARK Genomic Revolution ETF (ARKG) stake by 17% in Q2 2026, buying an estimated $26.5K and bringing the position to 5,611 shares worth $236K. The position accounts for 0.03% of the portfolio, ranked #238.

Valley National Advisers first reported a position in ARKG in Q4 2018 and has held it in 28 quarters since. The position peaked at $3.01M in Q2 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Valley National Advisers held 5,611 shares of ARK Genomic Revolution ETF worth $236K as of Q2 2026.
  • Valley National Advisers bought 833 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $26.5K.
  • ARK Genomic Revolution ETF made up 0.03% of Valley National Advisers's portfolio in Q2 2026, its #238 holding.
  • Valley National Advisers first reported a position in ARK Genomic Revolution ETF in Q4 2018 and has held it in 28 quarters since.
  • Valley National Advisers's ARK Genomic Revolution ETF position peaked at $3.01M in Q2 2021.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.